Cargando…
Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer
PURPOSE: To determine if models of ovarian clear cell carcinomas (OCCCs) harbouring defects in homologous recombination (HR) DNA repair of double strand breaks (DSBs) are sensitive to cisplatin and/or PARP inhibition. EXPERIMENTAL DESIGN: The HR status of 12 OCCC cell lines was determined using RAD5...
Autores principales: | Wilkerson, Paul M, Dedes, Konstantin J, Samartzis, Eleftherios Pierre, Dedes, Ioannis, Lambros, Maryou B, Natrajan, Rachael, Gauthier, Arnaud, Piscuoglio, Salvatore, Töpfer, Chantal, Vukovic, Vesna, Daley, Frances, Weigelt, Britta, Reis-Filho, Jorge S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351612/ https://www.ncbi.nlm.nih.gov/pubmed/28002809 http://dx.doi.org/10.18632/oncotarget.14011 |
Ejemplares similares
-
BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy
por: Soni, Aashish, et al.
Publicado: (2022) -
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
por: Herriott, Ashleigh, et al.
Publicado: (2015) -
Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro
por: Koppensteiner, Romana, et al.
Publicado: (2014) -
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast
por: Natrajan, Rachael, et al.
Publicado: (2014) -
A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)
por: Leal, Ticiana A., et al.
Publicado: (2022)